EPISODE 51 - Highlights of the 2025 NANETS Symposium
Download a Transcript of this Episode >>>
ABOUT THIS EPISODE
In this special annual episode, OHSU medical oncologist Dr. Guillaume (“Will”) Pegna joins us once again to break down the highlights from the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. He walks us through the latest clinical trial results and emerging research—covering PRRT, non-PRRT therapies, liver-directed treatments, and new biomarkers—and explains what these updates mean for the NET patient and caregiver community.
MEET DR. WILL PEGNA
Dr. Pegna is a medical oncologist who specializes in the care of adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors, including pheochromocytomas, paragangliomas and adrenocortical carcinomas as well as other gastrointestinal cancers.
Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient, and supporting them through their treatment journeys.
Highlights of the 2025 NANETS Symposium:
Clinical Trial Definitions
See also Glossary: Common Terms in Clinical Trials
Objective Response Rate (ORR) or Response Rate The percentage of patients whose tumors shrink by a meaningful amount after treatment.
Progression-Free Survival (PFS) The average length of time patients live without their cancer growing or worsening after starting treatment.
Overall Survival (OS) The average length of time patients are alive after starting a treatment, regardless of whether the cancer grows.
Disease Control Rate (DCR) The percentage of patients whose cancer is controlled by treatment, including those whose tumors shrink as well as those whose disease remains stable and does not grow.
Adverse Events (AEs)
Side effects that occur during or after treatment. Grade 3, 4, 5 are the concerning ones.
View the abstracts in the 2025 NANETS Symposium Abstract Booklet
PRRT
Capdevila J, et al. Efficacy of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase 3 COMPETE trial. Abstract C-14
Strosberg J, et al. Long-term Follow-up of PRRT-Naïve Patients with GEP- NETs Treated with Targeted Alpha Therapy 212Pb- DOTAMTATE in the Phase 2 ALPHAMEDIX 02 Trial. Abstract C-15 (Presented by Mary Maluccio.)
Strosberg J, et al. Phase 2 Study of Targeted Alpha Therapy 212Pb-DOTAMTATE in Patients with Advanced Gastroenteropancreatic (GEP)-NETs Previously Treated with PRRT. Abstract C-16
Chauhan A, et al. Efficacy and Safety of Peptide Receptor Radionuclide Therapy Retreatment (r-PRRT) Practices in Progressive Neuroendocrine Tumors (prog-NETs): Systematic Review and Meta-Analysis. Abstract C-27
*Check out the ongoing NET RETREAT Study in the NCF Clinical Trials Guide
THERAPEUTICS SECTION (NON-PRRT)
Chauhan A, et al. DAREON®-7: Phase I open-label dose-escalation/- expansion study of first-line obrixtamig (BI 764532) plus chemotherapy in patients with DLL3-positive neuroendocrine carcinomas. Abstract C-8.
Capdevila J, et al. An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression. Abstract C-1.
*Check out the ongoing DAREON®-7 Clinical Trial and the DAREON®-5 Clinical Trial
Sahwan O, et al. The Efficacy of Low-dose vs Standard-dose Everolimus in Patients with Advanced Neuroendocrine Tumors. Abstract C-10.
LOCAL REGIONAL THERAPIES
Soulen M, et al. Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET). Abstract C-12.
Kim J, et al. Safety of Transarterial Liver Directed Therapy for Metastatic Neuroendocrine Tumor for Patients with Carcinoid Heart Disease. Abstract C-25. (Presented by Nicholas Fidelman.)
Wornow, S, et al. Resection of Primary Pancreatic Neuroendocrine Tumors in the Metastatic Setting. Abstract C-44.
BIOMARKERS
Fu S, et al. Claudin 18.2 in pancreatic neuroendocrine tumors: a potential therapeutic target. Abstract B-13. (Presented by Garima Gupta.)
Singh A, et al. PPM1D as a Potential Driver of Myeloid Malignancy Transformation in Neuroendocrine Tumor (NET) Pts: An Underrecognized Malignant CHIPerpetrator? Abstract C-5.
Bendjennat M, et al. Validation of Adversity-Linked Genes in Pancreatic Neuroendocrine Tumors. Abstract B-2. (Presented by Andrea Gillis.)
HONORABLE MENTIONS
Dillon JS. Clinical integration of GLP-1 into patient care: Risks and clinical integration (MEN1, diabetes, syndromic patients, etc.). Oral presentation at the 2025 NANETS Annual Symposium.
Related peer-reviewed article: Shilyansky JS, Chan CJ, Xiao S, et al. GLP-1 receptor agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors. Surgery. 2025. PMID: 39665969.
*Check out the NCF podcast episode 49 where Dr. Dillon addresses GLP-1 drugs in NETs
Hallet J, et al. Care of Neuroendocrine Tumors: The Collaborative of Surgical Teams for NeuroEndocrine Tumors (CUTNETs). Abstract C-35.
NANETS
The North American Neuroendocrine Tumor Society (NANETS) provides NET medical educational programming designed exclusively for medical professionals. While our Podcast only features 11 presentations from the 2025 NANETS Symposium, there are many more noteworthy abstracts found (or listed) here:
While NANETS does not provide direct patient education, patients may help further NET education of medical professionals by sharing the organization's educational meetings and NET guidelines with their providers.
RESOURCES
Explore the NCF Clinical Trials Guide including study information, videos and resources.
DISCLAIMER
The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment.
THANK YOU TO OUR SPONSORS
